Biographical Sketch
Brian Bolwell, MD, is Director of the Bone Marrow Transplant Program at Cleveland Clinic and has held this position since 1988. In 2006, he was appointed as Chairman of the Department of Hematologic Oncology and Blood Disorders. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and has authored more than 300 articles and abstracts concerning hematologic malignancies and bone marrow transplantation. He also has edited a book entitled “Current Controversies in Bone Marrow Transplantation.” (Humana Press, 2000), and he is co-editor of a recently published textbook entitled “Clinical Malignant Hematology” (McGraw-Hill, 2007).
He attended Harvard University and he received his medical degree from Case Western Reserve University. He completed his medical internship and residency at University Hospitals of Cleveland and completed his hematology/oncology fellowship at the Hospital of the University of Pennsylvania.
Dr. Bolwell is a reviewer for many journals including the Journal of Clinical Oncology, Blood, Annals of Internal Medicine and Bone Marrow Transplantation. He has served, on multiple occasions, as a Bone Marrow Transplant (BMT) abstract reviewer and abstract session coordinating reviewer at the American Society of Hematology Annual meetings.
He has held the position of Chairman of the Board of Trustees of the Ohio Hematopoietic Stem Cell Transplant Consortium for more than 10 years. In 2004, he was elected to the Executive Committee of the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry. He is a member of the Board of Governors of Cleveland Clinic.
Specialty Interests
Bone Marrow Transplantation, Hodgkin's Disease, Leukemia
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 8/7/2008, Dr.
Bolwell has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Royalty Payments. Dr. Bolwell has the right to receive royalty payments for inventions or discoveries related to the companies shown below:
McGraw-Hill
